Date: 2014-07-23
Type of information: Initiation of preclinical development
phase: preclinical
Announcement: initiation of preclinical development
Company: Galapagos (Belgium) - Morphosys (Germany)
Product: MOR106
Action
mechanism: The novel mode of action for MOR106 remains undisclosed.
Disease:
Therapeutic area: Inflammatory diseases
Country:
Trial details:
Latest
news: * On July 23, 2014, MorphoSys and Galapagos announced that the first program from their strategic alliance has advanced into preclinical development. MOR106 was realized based on a novel Galapagos target and MorphoSys\' next-generation antibody library Ylanthia and will now be jointly developed in inflammatory diseases. MOR106 arises from the alliance initiated by Galapagos and MorphoSys in 2008, in which both companies contribute their core technologies and expertise. Galapagos provides the disease-related biology including the target and cellular assays. The targets are discovered using Galapagos\' SilenceSelect adenoviral target discovery platform. MorphoSys contributes its Ylanthia antibody technology to generate fully human antibodies directed against the target. Galapagos and MorphoSys will continue to share equally the research and development costs, as well as all future revenues.
